The startup develops biotechnology platforms for the oral delivery of drugs and biologics, focusing on oral insulin that prevents hypoglycemia and immune modulation to prevent type 1 diabetes without immune suppression. This technology addresses the challenges of effective drug delivery and management of complex metabolic conditions in the healthcare market.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of delivering insulin and modulating the immune system to prevent type 1 diabetes face significant challenges. Traditional insulin delivery can lead to hypoglycemia, while existing immune modulation techniques often result in broad immune suppression, increasing the risk of infection and other complications.
Solution
Endo Axiom is developing nanotechnology platforms for the oral delivery of drugs and biologics, specifically targeting diabetes and autoimmune diseases. Their lead programs focus on oral insulin that avoids hypoglycemia and immune modulation strategies that prevent type 1 diabetes without causing broad immunosuppression. By utilizing advanced drug delivery systems, Endo Axiom aims to improve the quality of life for individuals with diabetes and prevent the onset of autoimmune conditions through targeted immune interventions. The company's approach seeks to overcome the limitations of current treatments by providing safer, more effective, and patient-friendly solutions.
Target Audience
The primary target audience includes individuals with diabetes, those at risk of developing type 1 diabetes, and pharmaceutical companies seeking innovative drug delivery solutions for metabolic and autoimmune diseases.
Features
- Nanotechnology-based oral drug delivery platforms
- Oral insulin formulation designed to prevent hypoglycemia
- Immune modulation technology for targeted prevention of type 1 diabetes
- Focus on avoiding broad immune suppression associated with traditional methods
- Clinical validation of drug and biologic delivery systems